DNA Methylation-Based Classification for Central Nervous System Tumours

Project start date: March 2023 Status: In Development

Draft Recommendation

Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding DNA methylation–based classifier tests as an adjunct tool for the classification of central nervous system tumours when substantial clinical uncertainty remains after conventional testing.

We want to hear from you.

This topic is now available for public feedback until June 23, 2025. Please feel free to forward this page to any individual you think may be interested in reviewing this assessment. All comments will be considered before a final recommendation is made and posted here.

Use the tabs below to learn more about this topic, download supporting draft documents, including the full assessment report, and submit feedback.

Central nervous system tumours occur when abnormal cells form in the brain and/or spinal cord. Treatment strategy starts with classifying the tumour according to its characteristics – including size and malignancy (tendency to grow and spread). Recently, a test called the DNA methylation–based classifier test has been used in addition to established tests to help with tumour classification, especially tumours that have been difficult to classify using other methods.

This health technology assessment looked at how safe, effective, and cost-effective DNA methylation– based classifier testing is for central nervous system tumour classification. It also looked at the budget impact of publicly funding DNA methylation–based classifier tests.

Read the full health technology assessment report for more information.

DNA Methylation-Based Classification for Central Nervous System Tumours : A Health Technology Assessment (PDF)
May 2025

Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.

We reviewed evidence on DNA methylation–based classification for central nervous system tumours. Read the latest draft recommendation and share your feedback.

Submit Feedback

Date posted: June 3, 2025
Closing date for public comment: June 23, 2025

Evidence to Improve Care

DNA Methylation-Based Classification for Central Nervous System Tumours

Draft Recommendation

Let’s make our health system healthier

Join Our Patient, Family and Public Advisors Program

Sign up for our newsletter